Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
123 studies found for:    "Hyperlipoproteinemia type 2"
Show Display Options
Rank Status Study
1 Completed
Has Results
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: mipomersen sodium
2 Terminated Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
Conditions: Hyperlipoproteinemia Type II;   Homozygous Familial Hypercholesterolemia
Interventions: Drug: Anacetrapib;   Drug: Placebo
3 Active, not recruiting Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)
Conditions: Hyperlipoproteinemia Type II;   Heterozygous Familial Hypercholesterolemia
Interventions: Drug: Anacetrapib;   Drug: Placebo for Anacetrapib
4 Completed
Has Results
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: Mipomersen Sodium
5 Recruiting Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada
Conditions: Familial Hypercholesterolemia;   Lipid Disorder
Intervention:
6 Not yet recruiting Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).
Condition: Familial Hypercholesterolemia
Intervention: Biological: evolocumab (AMG 145)
7 Recruiting The Spanish Familial Hypercholesterolaemia Cohort Study
Condition: Familial Hypercholesterolaemia
Intervention:
8 Recruiting Russian Familial Hypercholesterolemia Registry
Condition: Familial Hypercholesterolemia
Intervention:
9 Completed Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
Condition: Homozygous Familial Hypercholesterolemia
Intervention: Drug: CER-001
10 Unknown  Postprandial Lipid Metabolism in Familial Hypercholesterolaemia:Effects of Fish Oils
Conditions: Hypertriglyceridaemia;   Familial Hypercholesterolaemia
Interventions: Dietary Supplement: Fish oil capsule;   Drug: HMG Coenzyme reductase
11 Recruiting MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)
Condition: Familial Hypercholesterolemia - Heterozygous
Intervention:
12 Completed
Has Results
An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia
Condition: Familial Hypercholesterolaemia
Intervention: Drug: rosuvastatin calcium
13 Completed
Has Results
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Interventions: Drug: mipomersen;   Drug: Placebo
14 Recruiting The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
Condition: Homozygous Familial Hypercholesterolemia
Intervention:
15 Completed Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
Condition: Familial Hypercholesterolemia
Intervention: Drug: lomitapide
16 Terminated Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy
Condition: Familial Hypercholesterolemia
Intervention: Drug: Implitapide
17 Terminated Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy
Condition: Familial Hypercholesterolemia
Intervention: Drug: Implitapide
18 Withdrawn Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients
Condition: Familial Hypercholesterolemia
Interventions: Drug: APL180;   Drug: Placebo
19 Completed Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia
Conditions: Heterozygous Familial Hypercholesterolemia;   Mixed Dyslipidemia
Intervention: Drug: Fluvastatin
20 Completed A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
Condition: Heterozygous Familial Hypercholesterolemia
Interventions: Drug: Bococizumab (PF-04950615;RN316);   Other: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years